Year All 2026 2025 2024 2023 2022 2021 2020 Sep 10, 2026 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors Sep 01, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 26, 2026 Candel Therapeutics to Present at September Investor Conferences Aug 13, 2026 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Aug 03, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2026 Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 Jul 29, 2026 Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston Jul 08, 2026 Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Jul 01, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30, 2026 Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Aug 13, 2026 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Aug 03, 2026 Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
Jul 29, 2026 Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
Jun 30, 2026 Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
